Premium
Stromelysin‐3 is expressed by aggressive meningiomas
Author(s) -
Perret Anne Gentil,
Duthel Robert,
Fotso MarieJeanette,
Bru Jacques,
Mosnier JeanFrançois
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10270
Subject(s) - meningioma , stromal cell , medicine , immunohistochemistry , pathology , proliferation index
BACKGROUND Stromelysin‐3 (ST3) that belongs to the metalloproteinase family is proposed to play a role in tumor invasion. The purpose of this work was to study the variation of ST3 expression in meningiomas. METHODS Twenty atypical meningiomas were retrieved from the Pathology Department's files at Hopital de Bellevue, Saint‐Etienne, France. They were compared with 20 benign meningiomas randomly selected from the same file. The tumors were classified using standard histologic criteria. Frozen sections of the tumors were immunostained for ST3 and MIB‐1 to evaluate the proliferative activity of tumor cells. RESULTS The study included 5 fibrous meningiomas, 10 transitional meningiomas, 20 syncitial meningiomas, 2 secretory meningiomas, 2 microcystic meningiomas, and 1 angiomatous meningioma. Stromelysin‐3 was expressed within the stromal and neoplastic cells of only 1 benign meningioma and 13 atypical meningiomas. The MIB‐1 proliferation index was significantly higher in the meningiomas expressing ST3 (Student t test: P < 0.001). The invasion of bone, muscle, and brain by meningiomas as well the recurrence were statistically correlated with their ST3 expression (Kruskal–Wallis nonparametric correlation test, P = 0.001 and P = 0.008, respectively). CONCLUSIONS Stromelysin‐3 might play an important role in the invasiveness of meningiomas. Therefore, considering, ST3 in association with evaluation of the MIB‐1 proliferating index may be an useful tool to assess the behavior of meningiomas. Cancer 2002;94:765–72. © 2002 American Cancer Society. DOI 10.1002/cncr.10270